Big drug developers reinvest revenues from cash-cow products to fuel the pipeline for the future.
News & Analysis: Vertex Pharmaceuticals
A large-cap biotech, a mid-cap biotech, and a small-cap biotech that have one thing in common: great growth prospects.
We examine three biotech companies' past performances and future outlooks.
The future looks bright for this big biotech.
Don't let Vertex's current valuation fool you. This elite biotech stock is a steal at current levels.
VRTX earnings call for the period ending December 31, 2019.
The company outperformed Wall Street expectations thanks to strong results from Trikafta.
The big biotech thinks it just might be able to cure type 1 diabetes.
One of these biotechs dominates the treatment of cystic fibrosis. The other doesn't have a single FDA-approved drug -- yet.
BeiGene and Vertex Pharmaceuticals aren't nearly as expensive as you may think.